The new laboratory will utilise expertise that already exists in the University’s Centre for Genomic Research and Institute of Integrative Biology
Scientists at the University of Liverpool have been awarded £2M to build a state-of-the-art DNA synthesis facility, a capability offering much needed tools for genome engineering to the academic and private sectors.
This facility, named GeneMill will be part of the UK’s focus on synthetic biology, identified by the Government as one of the ‘Eight Great Technologies’ in which Britain is, or can be, a world leader.
Synthetic biology involves the construction of artificial biological devices, pathways or networks or the re-engineering of existing natural ones. Key to this engineering process is the construction of parts or components, which are encoded in DNA. One of the biggest hurdles in synthetic biology is the creation and assembly of starting materials: modular bits of DNA that code for a particular function and are synthesised in the lab.
Creating such starting materials is time-consuming and expensive and a challenge that the Liverpool group of scientists will address through the GeneMill. Like traditional mills, scientists will take in raw materials and use them to create new products.
Through this approach the GeneMill will provide a rapid, cost-effective and accessible fabrication facility for DNA parts. By removing the complexity of manufacture for the user, GeneMill will allow researchers to focus on the design and testing of the re- engineered organisms which, amongst other areas, can be applied to produce novel chemicals, including new antibiotics and drugs and, at the large scale, feed stocks for the chemical industry.
Universities and Science Minister David Willetts said: “Synthetic biology is one of the eight great technologies of the future with the potential to underpin growth and create jobs in a low carbon economy. This investment in SynBio will hopefully stimulate even more interest and financial support and reinforce our efforts to develop a leading SynBio community in the UK.”
The new laboratory will utilise expertise in the application of DNA and protein technologies and computational biology that already exist in the University’s Centre for Genomic Research and in the Institute of Integrative Biology.
Plant biologist, Professor Anthony Hall, is the lead academic for the GeneMill project. He said: “This new lab will provide a resource for the whole of the North of England. It will add to a major concentration of technical expertise and facilities in synthetic and DNA technologies in Liverpool, which places the region at the forefront of research and development in this field.”
The funding has been provided by the Biotechnology and Biological Sciences Research Council (BBSRC) as part of a package of funding for synthetic biology made by Science Minister, David Willetts at the SynBioBeta Conference last night (Wednesday 2 April).
You must be logged in to post a comment.
All recent news
Obituary: Benny Pollack
Risk factors associated with severe and fatal cases of COVID-19 identified
Architecture academics on the view from your lockdown window
COVID-19 and alcohol – a dangerous cocktail
University lockdown lecturer engages with new audience online
"Just because Boris Johnson and the Prince of Wales have had #Covid19 doesn’t mean the disease strikes all people equally"
New @bmj_latest piece by @livuniHLS Profs Dame Margaret Whitehead, Ben Barr & David Taylor-Robinson #healthinequalities #LivUniCovid https://go.shr.lc/2LU5Gdm
We are not “all in it together”—less privileged in society are suffering the brunt of the damage https://blogs.bmj.com/bmj/2020/05/22/covid-19-we-are-not-all-in-it-together-less-privileged-in-society-are-suffering-the-brunt-of-the-damage/
@felly500 @BWDDPH @martinmckee @AbdulRazaq_PH @SimonCapewell99 @ProfBambra
Dr @soozaphone on @LivUniPsyc's new ‘Coping with COVID podcast’ that provides psychological support to medical, allied health professions and nursing students working in the #NHS during the #COVIDー19 pandemic.
More info https://bit.ly/2A5IOET